Testing levetiracetam for those at risk of Alzheimer's
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests if a medication called levetiracetam (a drug usually used for seizures) can help protect memory in people who are at higher risk for Alzheimer's but do not yet have memory problems. It involves brain scans and cognitive tests to see if the drug can reduce overactive brain activity linked to memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 55 to 85
- Normal memory and thinking skills (no dementia or mild cognitive impairment)
- At increased risk for Alzheimer's due to things like family history, memory concerns, or certain biomarkers (amyloid, tau, or APOE4)
- Have a specific type of brain activity called hippocampal hyperactivation (found on a special MRI scan)
- No history of epilepsy, recent seizures, or taking certain medications like seizure drugs or methotrexate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a single dose of levetiracetam, a medication that affects brain chemistry, can change brain function and thinking in people at risk for psychosis. The goal is to see if it might help prevent symptoms from worsening.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
This study looks at abnormal electrical activity in the brain that can happen in people with mild cognitive impairment or Alzheimer's disease. It aims to better understand this activity, which might help improve future treatments.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
Hear when a new Hippocampal Hyperactivation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.